Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Agios Pharmaceuticals Inc
CEO
Mr. Brian M. Goff M.B.A.
Employees
390
Industry
Biotechnology
Sector
Healthcare
Market cap
$2B
Company details
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$32.87M
Cost of goods (CoG)
-$3.49M
Gross profit (GP)
$29.38M
Operating expense (OE)
-$436.36M
Research and development (R&D)
-$295.96M
General and administrative (G&A)
-$140.39M
Operating income (OI)
-$406.98M
Other income expense (OIE)
-$1.10B
Pretax income (PI)
$727.43M
Tax (TAX)
-$53.12M
Net income (NI)
$674.31M
Stock vs Industry average
-
Industry average
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$11.96
Margin profit
2,051.38%
52 week low
$21.32
52 week high
$62.105
50-day simple moving average
$45.22
200-day simple moving average
$45.05
Percent held by insiders
1.51%
Percent held by institutions
107.73%
Dividend yield
0.00%
